Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q1 FY25 Earnings Presentation
24 slides from Alembic Pharmaceuticals's earnings presentation, Aug 8, 2024
Slide 1: Exchange intimation letter for investor presentation
Date: 8th August, 2024 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 533573
Slide 2: Investor Presentation Q1FY25
Alembic Pharmaceuticals Limited Investor Presentation Q1FY25 Aug 8, 2024
Slide 3: Safe Harbour Statement
Safe Harbour Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diff
Slide 4: Quarterly Snapshot
Quarterly Snapshot INR Bn Key Highlights : 5% YoY India Branded Business : India Branded Business Revenue R&D recorded 9% growth with topline of INR 5.72 billion 15.62 3% QoQ 7% of Sales for Q1 FY25. US Generics : Growth of 18% on YoY basis led by market share gain in few products and scaling up of
Slide 5: Revenue Snapshot
Revenue Snapshot INR Bn Business Q1 FY25 Q1 FY24 Y-o-Y Q4FY24 Q-o-Q Formulations India 5.72 5.24 9% 5.03 14% US 4.61 3.90 18% 4.23 9% Ex-US 2.71 2.66 2% 2.62 3% API 2.59 3.05 -15% 3.30 -22% Total Revenue 15.62 14.86 5% 15.17 3% Geographical Sales – Q1 FY25 India Business – Q1 FY25 Ex-US Vet 17% 17%
Slide 6: Diversified Therapy Presence
Diversified Therapy Presence Revenue – Q1 FY25 Revenue – Q1 INR Bn INR Bn Growth: 9% CAGR: 17.0% 5.72 5.24 572 0.98 524 0.80 480 480 Animal Health 1.30 1.32 Acute 306 Specialty 3.12 3.44 Q1FY24 Q1FY25 FY21 FY22 FY23 Axis Title FY24 FY25 Sales Mix Anti Infective Cough & Cold India Business recorded
Slide 7: Branded Business – Rx driven rankings
Branded Business – Rx driven rankings Top Brands with Rank and Market Share Driving overall Prescription Business *Figures in Mn Rank MS% Rank MS% BRANDS Q1 Q1 BRANDS Q1 Q1 130 0.23 47 FY 25* FY 25 FY 25* FY 25 AZITHRAL 1 35.3 WIKORYL 3 10.4 MAT Jun 24 ALTHROCIN 1 89.3 ISOFIT 3 5.4 MAT Jun 23 CRINA-
Slide 8: High focus therapies outgrowing market
High focus therapies outgrowing market Gynecology, Anti Diabetic and Ophthalmology have shown robust growth. Performed relatively better than the market in Antibiotic and Respiratory segments. Q1 FY25 Growth Comparison Therapy APL Market* Net Growth Gynaecology 12.5% 8.0% 4.5% Gastrointestinal 1
Slide 9: New Launches
New Launches New launches continue to do well along with promising future launches across key segments. Q1 FY25 Therapy Molecule Brands Launch INR Mn Dydrogesterone ISOFIT 2022 191 Gynecology Iron Ferric RICHAR-FCM/TUFEHART 2023 48 Raft Mkt ULGERAFT/EVARAFT/EXCERAFT 2022 86 Gastrointestinal Vonopraz
Slide 10: Animal Health Business
Animal Health Business Revenue – Q1 FY25 Revenue – Q1 Growth 23% CAGR 28.0% 976 795 717 Q1FY24 Q1FY25 980 529 800 364 Q1FY24 Q1FY25 FY21 FY22 FY23 FY24 FY25 Sales Mix Operating in Livestock and Poultry market Antibiotic 41% Leaders in Hematinic and Antibiotic market with Sharkoferrol, Moxel, Xce
Slide 11: Technology transforming business
Technology transforming business Deployment of Ipads for MR interaction with the Healthcare Medical Professional’s (HMP’s) - Upgrading our scope to communicate medico-marketing content to the HMP for our brands along with an increased time spend during calls. Upgraded to SalesForce platform for
Slide 12: US Business
US Business Revenue- Q1 FY25 Revenue – Last 5 years INR Bn INR Bn Growth 18% 4.61 3.90 21.63 19.76 17.30 16.66 15.72 Q1FY24 Q1FY25 FY20 FY21 FY22 FY23 FY24 Approved ANDAs Injectable 14 Well-established US front end with strong customer base Inhalation Derma 2 29 2 products launched in Q1FY25. Cumu
Slide 13: Ex-US Business
Ex-US Business Revenue – Q1 FY25 Revenue – Last 5 years INR Bn INR Bn Growth 2% 2.66 2.71 CAGR: 21% 10.52 8.52 7.79 7.75 Q1FY24 Q1FY25 Delivered 21% CAGR over last 5 years. 4.97 Ex-US driven by partnership in following key markets - Europe, Canada, Australia, Brazil and South Africa Sales operati
Slide 14: API Business
API Business Revenue – Q1 FY25 Revenue – Last 5 years INR Bn INR Bn 3.05 De-Growth (-15%) 2.59 CAGR: 15% 12.46 11.66 9.55 9.39 Q1FY24 Q1FY25 7.08 Decline of 15% on YoY basis, largely led by low off-take from few selected customers - transitionary in nature. 1 US DMF filed in Q1 FY25. 133 Cumulativ
Slide 15: R&D
R&D Dosage form wise ANDA approval and Launch R&D Capabilities Q1FY25 Dosage Forms Formulation : Vadodara and Hyderabad Approval* Launch OSD 7 1 API : Vadodara and Hyderabad Injectable - Gen 2 0 Bio Centre : Vadodara Injectable - Onco 0 0 Ophthalmology 0 0 Dermatology 2 1 Other 0 0 Total 11 2 *Inclu
Slide 16: Yearly Financials
Yearly Financials Revenue INR Bn EBIDTA Net Profit INR Bn INR Bn 16.31 11.78 62.29 10.53 # 9.61 56.53 7.79 # 6.65 # 6.16 53.93 4.97 # 53.06 FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 EBIDTA margin % Capex INR Bn ROCE % 41 * 30 6.87 20 # 4.67 25*# 15 4.12 14 # 3.45 14*# 15 FY21 FY22
Slide 17: Enhancing ESG compliance
Sustainability Enhancing ESG compliance Commissioned 12 MW Solar park at Bhatpur, Gujarat Targets: Developed 82 Nos. of recharge well and planted 20,000 Trees so far 19% Reduction in Indirect Energy Consumption 28% Reduction in Water Consumption(KL/MT) Net-Zero by 2040 16% Reduction (YoY) in To
Slide 18: Strategic Roadmap
Strategic Roadmap Business Initiatives in FY24 Plan for FY25 • Increased focus on the animal health space with therapy leading products. • Improve depth in the current strength with new launches • Deployment of Ipads for MR interaction with the planned in FY 25 & launches done in FY 24. The India Bu
Slide 19: Company Overview
Company Overview
Slide 20: Company at a Glance
Company at a Glance Mission Prescribers in India Improve healthcare with innovation, commitment and trust 2,33,000 Team size Field Force 14,500 + 5,000 + Brands Manufacturing facilities 9 191 ANDA filings Net Zero 262 (June 30, 2024) 2040 R&D Centres Products in US 2 149
Slide 21: Value Proposition
Value Proposition Developing Supplying APIs Ranks 20th in the specialty drug to 60+ countries Indian formulations pipeline for India globally market Exploring Consistent and Established a opportunities in High Dividend presence in Chile Injectables Payout & UAE Strengthening presence Expanding in Ca
Slide 22: The Journey
The Journey 1907 2007 2008 2009 2010 2012 2006 Acquired Dabur’s FDA approved Pharmaceutical Established by FDA approved FDA approved APIIndian Cardiology, facility FDA approved Multiple divisions to business demerged Formed a JV, Amin Family GI and Gynecology Formulation address chronic API facility
Slide 23: Robust Infrastructure
Robust Infrastructure Last USFDA Location Dosage Form Audit International Generics F1 – Panelav General Oral Solids Jul’24 Oncology Oral Solids Mar’24 F2 – Panelav Oncology Injectables Mar’24 F2 - F3 - General Injectables Panelav Karkhadi F3 – Karkhadi Ophthalmic Mar’23 F4 – Jarod General Oral Solid
Slide 24: Thank you
For further queries, please contact: Mr. Ajay Desai ajay.desai@alembic.co.in 022-6695 3999 Thank you Investor Relations Advisors : Adfactors PR Pvt. Ltd. Snighter Albuquerque snighter.a@adfactorspr.com Darshan Mankad darshan.mankad@adfactorspr.com
Alembic Pharmaceuticals — Q1 FY25 Earnings Presentation on 6ix